NCT07734636 A Prompt REstart Study of Renin-Angiotensin System Inhibitors After Acute Kidney Injury
| NCT ID | NCT07734636 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | University of California, San Francisco |
| Condition | Acute Kidney Injury |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2026-09-01 |
| Primary Completion | 2029-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 60 participants in total. It began in 2026-09-01 with a primary completion date of 2029-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this pilot clinical trial is to learn if early restart of renin-angiotensin system inhibitor (RASi) medications is feasible and well-tolerated in hospitalized patients with acute kidney injury (AKI). Researchers will compare early RASi restart to usual care. Study participants will restart RASi per study protocol, obtain a lab test in 1-2 weeks if RASi restarted in the hospital and not collected as part of routine care, and answer questions at the 90-day follow-up.
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years * Pre-admission RASi use for Class I indication (e.g., heart failure, kidney disease) * RASi stopped in the setting of AKI (defined by ≥1.5x baseline SCr) * AKI in recovery (defined by a decrease in SCr by ≥0.3mg/dL from peak) Exclusion Criteria: * RASi allergy or contraindication (i.e., angioedema, bilateral renal artery stenosis) * Ongoing dialysis requirement * Pregnant or breastfeeding * Prisoner * Palliative or hospice care involvement * Unable to consent * No enteral route of medication administration * Clinician judgment
Contact & Investigator
Yuenting D Kwong, MD MAS
PRINCIPAL INVESTIGATOR
University of California, San Francisco
Frequently Asked Questions
Who can join the NCT07734636 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Acute Kidney Injury. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07734636 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT07734636 currently recruiting?
Yes, NCT07734636 is actively recruiting participants. Contact the research team at diana.kwong@ucsf.edu for enrollment information.
Where is the NCT07734636 trial being conducted?
This trial is being conducted at San Francisco, United States.
Who is sponsoring the NCT07734636 clinical trial?
NCT07734636 is sponsored by University of California, San Francisco. The principal investigator is Yuenting D Kwong, MD MAS at University of California, San Francisco. The trial plans to enroll 60 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.